Opaleye Management »

Monte Rosa Therapeutics shares owned by Opaleye Management

Quarter-by-quarter ownership of Monte Rosa Therapeutics (GLUE) shares owned by Opaleye Management from 13F filings

Historical chart of Opaleye Management investment in Monte Rosa Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Monte Rosa Therapeutics held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Monte Rosa Therapeutics by Opaleye Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $18M 745k 24.20

More positions owned by Opaleye Management

Liquidia Corporation Com New (LQDA)
Eton Pharmaceuticals (ETON)
Harrow Health (HROW)
Disc Medicine (IRON)
Urogen Pharma (URGN)
Apogee Therapeutics (APGE)
Meiragtx Holdings (MGTX)
Sol-gel Technologies Shs New (SLGL)
Rezolute Com New (RZLT)
Tg Therapeutics (TGTX)
Immix Biopharma (IMMX)
Crescent Biopharma (CBIO)
Stoke Therapeutics (STOK)
Alpha Cognition Com New (ACOG)
Edgewise Therapeutics (EWTX)

View all positions for Opaleye Management

Top funds holding Monte Rosa Therapeutics

NEA Management Company
BlackRock
T. Rowe Price Associates
TCG Crossover Management
Vestal Point Capital
BVF
Baker Bros. Advisors
Suvretta Capital Management
Vanguard Capital Management
State Street Corporation
Versant Venture Management
Braidwell
Geode Capital Management
American Century Companies
Marshall Wace

View all funds holding Monte Rosa Therapeutics